1-5 1-6 sent to printer.) COMMITTEE VOTE 1-7 1-8 Absent PNV Yea Nay 1-9 Whitmire Х 1-10 1-11 Х Huffman Х Burton 1-12 Х <u>Creighton</u> 1-13 Hinojosa Х 1-14 Х Menéndez 1-15 Perry Х 1-16 COMMITTEE SUBSTITUTE FOR S.B. No. 173 By: Huffman 1-17 A BILL TO BE ENTITLED 1-18 AN ACT 1-19 relating to the designation for criminal prosecution and other purposes of certain chemicals commonly referred to as synthetic cannabinoids as controlled substances and controlled substance 1-20 1-21 1-22 analogues under the Texas Controlled Substances Act. 1-23 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: 1-24 SECTION 1. Sections 481.002(5) and (6), Health and Safety Code, are amended to read as follows: (5) "Controlled substance" means 1-25 1-26 1-27 substance, а substed in including a drug, an adulterant, and a dilutant, listed in Schedules I through V or Penalty Group [Groups] 1, 1-A, [or] 2, 2-A, 1-28 3, or [through] 4. The term includes the aggregate weight of any mixture, solution, or other substance containing a controlled 1-29 1-30 1-31 substance. 1-32 "Controlled substance analogue" means: (6)1-33 (A) a substance with a chemical structure 1-34 substantially similar to the chemical structure of a controlled 1-35 substance in Schedule I or II or Penalty Group 1, 1-A, [or] 2, or 1-36 <u>2-A</u>; or 1-37 (B) a substance specifically designed to produce 1-38 an effect substantially similar to, or greater than, the effect of a 1-39 controlled substance in Schedule I or II or Penalty Group 1, 1-A, [or] 2<u>, or 2-A</u>. SECTION 2. 1-40 Section 481.1031, Health and Safety Code, is 1-41 1-42 amended to read as follows: Sec. 481.1031. PENALTY GROUP 2-A. (a) In this section: (1) "Core component" means one of the following 1-43 1-44 groups: benzimidazole, benzothiazole, carbazole, indane, indazole, indene, indole, pyrazole, 1-45 <u>func</u>tional imidazole, indane, indazole, indene, indole, pyrazole, pyrazolopyridine, or pyrrole. (2) "Group A component" means one of the following functional groups: adamantane, benzene, cycloalkylmethyl, imidazole, 1-46 1-47 1-48 1-49 isoquinoline, methylpiperazine, naphthalene, phenyl, quinoline, 1-50 tetrahydronaphthalene, tetramethylcyclopropane, amino oxobutane, amino dimethyl oxobutane, amino phenyl oxobutane, methyl methoxy oxobutane, methoxy dimethyl oxobutane, methoxy phenyl oxobutane, 1-51 1-52 1-53 or an amino acid. (3) "Link component" means one of the following 1-54 1-55 <u>functional groups: carboxamide, carboxylate, methanone (ketone),</u> <u>ethanone, methanediyl (methylene bridge), or methine.</u> <u>(b)</u> Penalty Group 2-A consists of <u>any material, compound</u>, 1-56 1-57 1-58 mixture, or preparation that contains any quantity of a natural or synthetic chemical substance, including its salts, isomers, and 1-59 1-60 1

1-1 By: Huffman S.B. No. 173 (In the Senate - Filed November 10, 2014; January 27, 2015, read first time and referred to Committee on Criminal Justice; March 16, 2015, reported adversely, with favorable Committee 1-2 1-3 1-4 Substitute by the following vote: Yeas 7, Nays 0; March 16, 2015,

	C.S.S.B. No. 173
	listed by name in this subsection or contained
	<pre>structural classes defined in this subsection: VIN-55,212-2;</pre>
	Cyclohexylphenol: any compound [that is a
5 cannabinoid recep	tor agonist and mimics the pharmacological effect
	rring cannabinoids, including: choylindoles structurally derived from
	choylindoles structurally derived from deriv
indole ring by al	kyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
	yl)ethyl, whether or not further substituted in
	to any extent, whether or not substituted in the average of the average of the average of the average of the substituted in the su
<u>F</u> <u>7</u> <u>5</u>	[AM=2201;
	[JWH-004;
	[JWH=007; [JWH=009;
	[JWH=015;
	[JWH-016;
	[JWH-018; [JWH-019;
	[JWH=020;
	[JWH-046;
	[JWH-047; [JWH-048;
	[JWH=040; [JWH=049;
	[JWH=050;
	[JWH=073;
	[JWH-076; [JWH-079;
	[JWH=080;
	[JWH-081;
	[JWH-082; [JWH-083;
	[JWH-093;
	[JWH-094;
	[JWH-095; [JWH-096;
	JWH-097;
	[JWH-098;
	[JWH-099; [JWH-100;
	[JWH=116;
	[JWH-122;
	[JWH-148; [JWH-149;
	[JWH=153;
	[JWH=159;
	[JWH-164; [JWH-165;
	[JWH=166;
	[JWH-180;
	[JWH-181; [JWH-182;
	[JWH-189;
	[JWH-193;
	[JWH-198; [JWH-200;
	[JWH=210;
	[JWH-211;
	[JWH-212; [JWH-213;
	[JWH=234;
	[JWH=235;
	[JWH-239; [JWH-240;
	[JWH=240; [JWH=241;
	JWH-242;
	[JWH-258; [JWH-259;
	l um=2Jÿ;

	C.S.S.B. No. 173
3-1	[JWH-260;
3-2	[JWH-262;
3-3	$\left[\frac{JWH-267}{JWH-267}\right]$
3-4	[JWH=386;
-	- ,
3-5	[JWH=387;
3-6	[JWH=394;
3-7	JWH-395;
	[JWH=397;
3-8	
3-9	[JWH=398;
3-10	[JWH-399;
3-11	[JWH=400;
3-12	[JWH=412;
3-13	[JWH=413; and
3-14	JWH-414;
3-15	- /
	[naphthylmethylindones structurally derived from
3-16	1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen
3-17	atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl,
3-18	cycloalkylethyl, or 2-(4-morpholinyl)ethyl, whether or not further
3-19	substituted in the indole ring to any extent, whether or not
	Substituted in the induce ring to any extent, whether of not
3-20	substituted in the naphthyl ring to any extent, including:
3-21	[JWH=175;
3-22	[JWH-184;
3-23	[JWH=185;
3-24	[JWH-192;
3-25	[JWH=194;
3-26	[JWH-195;
3-27	[JWH=196;
3-28	[JWH=197; and
3-29	[JWH=199;
3-30	[naphthoylpyrroles structurally derived from
3-31	3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the
3-32	pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
3-33	or 2-(4-morpholinyl)ethyl, whether or not further substituted in
3-34	the pyrrole ring to any extent, whether or not substituted in the
3-35	naphthyl ring to any extent, including:
3-36	[JWH=030;
3-37	[JWH=145;
3-38	[JWH=146;
3-39	[JWH=147;
	$\left[\frac{\text{JWH}-177}{\text{JWH}-150}\right]$
3-40	
3-41	[JWH=156;
3-42	[JWH=243;
3-43	JWH-244;
	- /
3-44	[JWH=245;
3-45	[JWH=246;
3-46	[JWH=292;
3-47	[JWH=293;
3-48	[JWH=307;
3-49	[JWH=308;
3-50	[JWH-309;
3-51	[JWH-346;
3-52	[JWH=347;
3-53	[JWH=348;
3-54	[JWH=363;
3-55	[JWH=364;
3-56	[JWH=365;
3-57	[JWH-366;
3-58	[JWH=367;
3-59	[JWH=368;
3-60	[JWH=369;
	- /
3-61	[JWH=370;
3-62	[JWH=371;
3-63	[JWH-372;
3-64	$\left[\frac{JWH-373}{JWH-373}\right]$ and
3-65	$\left[\frac{\partial WH - 392}{\partial WH - 392}\right]$
	- /
3-66	[naphthylmethylindenes structurally derived from
3-67	1-(1-naphthylmethyl)indene by substitution at the 3-position of
3-68	the indene ring by alkyl, alkenyl, cycloalkylmethyl,
3-69	
5-09	cycloalkylethyl, or 2-(4-morpholinyl)ethyl, whether or not further

C.S.S.B. No. 173 the indene ring to any 4-1 substituted in extent, whether or not 4-2 substituted in the naphthyl ring to any extent, including: JWH-171; 4-3 4 - 4. JWH-172; [JWH=173; and 4-5 [JWH=176; 4-6 4-7 [phenylacetylindoles structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the 4-8 alkyl, alkenyl, 4-9 ring with indole cycloalkylethyl, or 2-(4-morpholinyl)ethyl, whether or not further 4-10 4-11 the indole ring to any extent, whether substituted in or not 4-12 substituted the phenyl ring to any extent, including: in [AM-694; 4-13 AM-1241; 4-14 4**-**15 4**-**16 [JWH**-**167; [JWH-203; 4-17 [JWH-204; [JWH-205; 4-18 4-19 [JWH-206; 4-20 4-21 [JWH-208; [JWH-237; 4-22 [JWH-248; [JWH**-**249; 4 - 2.34-24 [JWH=250; 4-25 [JWH=251; 4-26 [JWH=252; 4-27 [JWH-253; [JWH-302; 4-28 4-29 [JWH-303; 4-30 [JWH-305; 4-31 JWH-306; [JWH=311; 4-32 [JWH-312; 4 - 33[JWH**-**313; 4-34 [JWH**-**314; and 4-35 4-36 [JWH=315; 4-37 [cyclohexylphenols] structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of 4-38 4-39 the phenolic ring [by alkyl], (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl [alkenyl, cycloalkylmethyl, cycloalkylethyl, or 2-(4-morpholinyl)ethyl], 4-40 4-41 4-42 whether or not substituted in the cyclohexyl ring to any extent, 4-43 including: <u>JWH-337;</u> <u>JWH</u>-344; 4 - 444-45 CP-55,940; 4-46 4-47 CP-47,497; and analogues of CP-47,497; 4-48 VII, Cannab<u>inol</u>[, including 4-49 (3)V, VTTT Т TTT XIII, XV, and XVI; 4-50 IX, . JWH-337; 4-51 4-52 [JWH=344; 4-53 [JWH**-**345; and [JWH=405; and 4-54 [cannabinol] derivatives, except where contained in marihuana, including tetrahydro derivatives of cannabinol and 4-55 4-56 4-57 3-alkyl homologues of cannabinol or of its tetrahydro derivatives, 4-58 such as: 4-59 Nabilone; 4-60 HU-210; and HU-211; 4-61 4-62 Tetramethylcyclopropyl thiazole: (4)any compound structurally derived from 2,2,3,3-tetramethyl-N-(thiazol-4-63 2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen 4-64 atom of the thiazole ring, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the 4-65 4-66 tetramethylcyclopropyl ring to any extent, including: 4-67 <u>A-836,339;</u> 4-68 (5) 4-69 any compound containing a core component

	C.S.S.B. No. 173
5-1	substituted at the 1-position to any extent, and substituted at the
5-2	3-position with a link component attached to a group A component,
5-3	whether or not the core component or group A component are further
5-4	substituted to any extent, including:
5-5	Naphtoylindane;
5-6	Naphthoylindazole (THJ-018);
5-7	Naphthyl methyl indene (JWH-171);
5-8	Naphthoylindole (JWH-018);
5-9	Quinolinoyl pyrazole carboxylate (Quinolinyl
5-10	fluoropentyl fluorophenyl pyrazole carboxylate);
5-11	Naphthoyl pyrazolopyridine; and
5-12	Naphthoylpyrrole (JWH-030);
5-13	(6) any compound containing a core component
5-14	substituted at the 1-position to any extent, and substituted at the
5-15	2-position with a link component attached to a group A component,
5-16	whether or not the core component or group A component are further
5-17	substituted to any extent, including:
5-18	Naphthoylbenzimidazole (JWH-018 Benzimidazole);
5-19	and
5-20	Naphthoylimidazole;
5-21	(7) any compound containing a core component
5-22	substituted at the 3-position to any extent, and substituted at the
5-23	2-position with a link component attached to a group A component,
5-24	whether or not the core component or group A component are further
5-25	substituted to any extent, including:
5-26	Naphthoyl benzothiazole; and
5-27	(8) any compound containing a core component
5-28	substituted at the 9-position to any extent, and substituted at the
5-29	3-position with a link component attached to a group A component,
5-30	whether or not the core component or group A component are further
5-31	substituted to any extent, including:
5-32	Naphthoylcarbazole (EG-018) [and
5-33	[WIN-55,212-2].
5 - 34	SECTION 3. Section 481.106, Health and Safety Code, is
5-35	amended to read as follows:
5-36	Sec. 481.106. CLASSIFICATION OF CONTROLLED SUBSTANCE
5-37	ANALOGUE. For the purposes of the prosecution of an offense under
5-38	this subchapter involving the manufacture, delivery, or possession
5-39	of a controlled substance, Penalty Groups 1, 1-A, [and] 2, and 2-A
5-40	include a controlled substance analogue that:
5-41	(1) has a chemical structure substantially similar to
5-42	the chemical structure of a controlled substance listed in the
5-43	applicable penalty group; or
5-44	(2) is specifically designed to produce an effect
5-45	substantially similar to, or greater than, a controlled substance
5-46	listed in the applicable penalty group.
5-47	SECTION 4. The change in law made by this Act applies only
5-48	to an offense committed on or after the effective date of this Act.
5-49	An offense committed before the effective date of this Act is
5-50	governed by the law in effect on the date the offense was committed,
5-51	and the former law is continued in effect for that purpose. For
5-52	purposes of this section, an offense was committed before the
5-53	effective date of this Act if any element of the offense occurred
5-54	before that date.
5-55	SECTION 5. This Act takes effect September 1, 2015.

5-56

* * * * *